-+ 0.00%
-+ 0.00%
-+ 0.00%

Gene One Life Science says VGXI’s USD 2 million first option-payment date under buyback extension is under renegotiation

PUBT·10/08/2026 10:43:31
Listen to the news
Gene One Life Science says VGXI’s USD 2 million first option-payment date under buyback extension is under renegotiation
  • Gene One Life Science issued a correction on Oct. 8 to a subsidiary disclosure tied to VGXI’s buyback option for its Conroe plant.
  • The filing removed the Oct. 7 payment date for the first USD 2 million deposit, citing ongoing talks to delay the payment.
  • The total buyback exercise amount remains USD 39.9 million, with a revised contract expected to trigger another correction filing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008800890), on October 08, 2026, and is solely responsible for the information contained therein.